Dr. Spencer Nadolsky

I was so ravenously hungry and craving. And what my patients described was kind of that. So I could imagine them being, you know, in a 300 pound or 250 pound body with a lot of excess adipose tissue, trying to lose weight and feeling that way. Just that, you know, I was already really lean, but like they're feeling that way at a higher body fat.

I was so ravenously hungry and craving. And what my patients described was kind of that. So I could imagine them being, you know, in a 300 pound or 250 pound body with a lot of excess adipose tissue, trying to lose weight and feeling that way. Just that, you know, I was already really lean, but like they're feeling that way at a higher body fat.

I was so ravenously hungry and craving. And what my patients described was kind of that. So I could imagine them being, you know, in a 300 pound or 250 pound body with a lot of excess adipose tissue, trying to lose weight and feeling that way. Just that, you know, I was already really lean, but like they're feeling that way at a higher body fat.

That's what made me go like, oh man, I think I missed the mark.

That's what made me go like, oh man, I think I missed the mark.

That's what made me go like, oh man, I think I missed the mark.

It's exhausting. It's exhausting. Like a game of pickleball could be, I suppose.

It's exhausting. It's exhausting. Like a game of pickleball could be, I suppose.

It's exhausting. It's exhausting. Like a game of pickleball could be, I suppose.

that do just fine on a little dose and go through your journey, just fine, no issues. And that does happen. However, I would say it's not rare. It's still uncommon, but common enough when you have hundreds of patients that you see some of these side effects, especially at the higher doses that get brushed off by someone if they don't listen.

that do just fine on a little dose and go through your journey, just fine, no issues. And that does happen. However, I would say it's not rare. It's still uncommon, but common enough when you have hundreds of patients that you see some of these side effects, especially at the higher doses that get brushed off by someone if they don't listen.

that do just fine on a little dose and go through your journey, just fine, no issues. And that does happen. However, I would say it's not rare. It's still uncommon, but common enough when you have hundreds of patients that you see some of these side effects, especially at the higher doses that get brushed off by someone if they don't listen.

For example, the one that I'm seeing more recently and I've made some videos on is anhedonia, just kind of feeling meh, blah. And it actually happened quickly in 2022 when Manjaro came out. We were all using it off-label. Everybody's like, oh, how dare you use that drug off-label? I'm like, well, the Surmount trial was out. It just wasn't available as that found yet.

For example, the one that I'm seeing more recently and I've made some videos on is anhedonia, just kind of feeling meh, blah. And it actually happened quickly in 2022 when Manjaro came out. We were all using it off-label. Everybody's like, oh, how dare you use that drug off-label? I'm like, well, the Surmount trial was out. It just wasn't available as that found yet.

For example, the one that I'm seeing more recently and I've made some videos on is anhedonia, just kind of feeling meh, blah. And it actually happened quickly in 2022 when Manjaro came out. We were all using it off-label. Everybody's like, oh, how dare you use that drug off-label? I'm like, well, the Surmount trial was out. It just wasn't available as that found yet.

It wasn't approved yet, but the Phase 3 trial was out. So we were using it for obesity a lot. And people were feeling tired. And you see it with WeGoV2, the semaglutide. But terzapatide, we were seeing it and people were like, well, it's got to be from the calorie deficit. And that makes sense that people would feel tired from a calorie deficit.

It wasn't approved yet, but the Phase 3 trial was out. So we were using it for obesity a lot. And people were feeling tired. And you see it with WeGoV2, the semaglutide. But terzapatide, we were seeing it and people were like, well, it's got to be from the calorie deficit. And that makes sense that people would feel tired from a calorie deficit.

It wasn't approved yet, but the Phase 3 trial was out. So we were using it for obesity a lot. And people were feeling tired. And you see it with WeGoV2, the semaglutide. But terzapatide, we were seeing it and people were like, well, it's got to be from the calorie deficit. And that makes sense that people would feel tired from a calorie deficit.

However, there were people that weren't losing weight, any weight. They didn't feel like any appetite suppression, but they were feeling tired. And so it's kind of like, okay, if they're not losing weight, they're not in a calorie deficit, they don't even feel the appetite suppression, but they're feeling tired, it's probably something beyond the calorie deficit that's making people feel tired.

However, there were people that weren't losing weight, any weight. They didn't feel like any appetite suppression, but they were feeling tired. And so it's kind of like, okay, if they're not losing weight, they're not in a calorie deficit, they don't even feel the appetite suppression, but they're feeling tired, it's probably something beyond the calorie deficit that's making people feel tired.